Dr. Labiento Smith controls early myopia progression with low-dose Atropine and/or Orthokeratology. She bases her treatment on the current literature and recent LAMP study. These treatments for myopia control are considered an off-label use in the United States.. The medication Atropine and Ortho-K are FDA approved but under a different category and use. All children with active myopia progression at Sudbury Eye Care are seen bi-annually for exams to monitor progression.
What a fantastic place the people are incredibly nice not to mention a local company which means they are more willing to work with you they care about each individual client I’d much rather support the little guy in a big company wouldn’t you?
Jacob K. — Yelp